Filing Details
- Accession Number:
- 0001415889-25-011569
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-04-30 16:08:50
- Reporting Period:
- 2025-03-27
- Filing Date:
- 2025-04-30
- Accepted Time:
- 2025-04-30 16:08:50
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1785530 | Werewolf Therapeutics Inc. | HOWL | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1134655 | Ansbert Gadicke | C/O Mpm Bioimpact Llc 399 Boylston Street, Suite 1100 Boston MA 02116 | No | No | No | No | |
| 1263048 | Mpm Asset Management Llc | C/O Mpm Bioimpact Llc 399 Boylston Street, Suite 1100 Boston MA 02116 | No | No | Yes | No | |
| 1687078 | Mpm Bioimpact Llc | C/O Mpm Bioimpact Llc 399 Boylston Street, Suite 1100 Boston MA 02116 | No | No | Yes | No | |
| 1691428 | L.p. Fund Impact Oncology Ubs | C/O Mpm Bioimpact Llc 399 Boylston Street, Suite 1100 Boston MA 02116 | No | No | Yes | No | |
| 1719960 | Mpm Oncology Innovations Fund Lp | C/O Mpm Bioimpact Llc 399 Boylston Street, Suite 1100 Boston MA 02116 | No | No | Yes | No | |
| 1721036 | L.p. Management (Cayman) Fund Impact Oncology | C/O Mpm Bioimpact Llc 399 Boylston Street, Suite 1100 Boston MA 02116 | No | No | Yes | No | |
| 1857903 | Mpm Oncology Innovations Fund Gp Llc | C/O Mpm Bioimpact Llc 399 Boylston Street, Suite 1100 Boston MA 02116 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2025-03-27 | 50,873 | $0.09 | 6,723,056 | No | 4 | X | Indirect | See Footnote |
| Common Stock | Disposition | 2025-03-27 | 4,386 | $1.05 | 6,718,670 | No | 4 | S | Indirect | See Footnote |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | X | Indirect | See Footnote |
| No | 4 | S | Indirect | See Footnote |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Warrant (Right to Buy) | Disposition | 2025-03-27 | 8,031 | $0.00 | 8,031 | $0.09 |
| Common Stock | Warrant (Right to Buy) | Disposition | 2025-03-27 | 42,842 | $0.00 | 42,842 | $0.09 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2025-04-09 | No | 4 | X | Indirect | |
| 0 | 2025-08-13 | No | 4 | X | Indirect |
Footnotes
- On March 27, 2025, the Reporting Persons exercised warrants to purchase an aggregate of 50,873 shares of the Company's Common Stock for $0.09 per share. The Reporting Persons paid the exercise price on a cashless basis, resulting in the Company's withholding of 4,386 of the warrant shares to pay the exercise price and issuing the remaining 46,487 shares.
- The shares are held as follows: 461,408 by MPM Asset Management LLC ("AM LLC"), 2,915,905 by MPM BioVentures 2014, L.P. ("BV 2014"), 194,486 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 100,365 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 640,121 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 2,410,771 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC and a manager of MPM OIF GP. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
- MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
- The shares are held as follows: 461,408 by AM LLC, 2,914,123 by BV 2014, 194,367 by BV 2014(B), 100,303 by AM BV2014, 639,659 by MPM OIF and 2,408,810 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
- Immediately exercisable.
- The warrants were held as follows: 3,647 by BV 2014, 243 by BV 2014(B), 125 by AM BV 2014 and 4,016 by UBS Oncology.
- The warrants were held as follows: 17,023 by BV 2014, 1,135 by BV 2014(B), 585 by AM BV 2014, 5,355 by MPM OIF and 18,744 by UBS Oncology.
Billionaire Hedge Funds
